Roche partner Zealand posts Phase 2 data for amylin obesity drug
罗氏合作伙伴Zealand Pharma公布胰淀素减重药物的II期数据

Zealand Pharma is out with the Phase 2 data for an amylin analog that spurred one of the industry’s largest-ever obesity drug deals last year.
Zealand Pharma公布了一种胰淀素类似物在II期临床中的数据，这一候选药物曾在去年促成了业内史上最大规模的肥胖症药物交易之一。